fibrosis/hypoxia

This application is a U.S. National Stage application of co-pending PCT application PCT/GB2004/002755, filed Jun. 24, 2004, which claims the priority of Great Britain Patent Application No. 0315111.5, filed Jun. 27, 2003. These applications are incorporated herein by reference in their

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the United States national phase of International Application No. PCT/IB2016/055565 filed Sep. 17, 2016, and claims priority to Indian Patent Application No. 918/MUM/2015 filed Sep. 19, 2015, the disclosures of which are hereby incorporated

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for preventing and/or treating osteoporosis and other disease states in animal subjects, utilizing organic boron compounds. 2. Description of the Related Art The adult skeleton is composed of 80% cortical

TECHNICAL FIELD OF THE INVENTION This invention is related to the area of pulmonary, cardiac, and inflammation disorders. In particular, it relates to methods for treatment of these disorders and screening for therapeutic agents to treat these disorders. BACKGROUND OF THE INVENTION Hypoxia-induced

FIELD Provided herein are aldehyde compounds for use in treating diseases such as pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal. BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a deadly lung

FIELD Provided herein are aldehyde compounds for use in treating diseases such as pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal. BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a deadly lung

FIELD Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde (hereinafter "Compound 1" or "voxelotor"), formulations and compositions of Compound 1, and processes of manufacturing such tablets. The present

CROSS-REFERENCE TO RELATED APPLICATION This application is the 35 U.S.C. .sctn.371 national stage application of PCT Application No. PCT/EP2014/071543, filed Oct. 8, 2014, which claims priority to and the benefit of, FR Patent Application No. 1302334, filed Oct. 8, 2013, both of which are herein

CROSS REFERENCE TO RELATED APPLICATION The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995. BACKGROUND OF THE INVENTION This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives. Nitric Oxide in

BACKGROUND OF THE INVENTION This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines. Nitric Oxide in Biology. The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological